Hims & Hers Health (HIMS) – Research Analysts’ Recent Ratings Updates

A number of research firms have changed their ratings and price targets for Hims & Hers Health (NYSE: HIMS):

• 11/10/2026 – Hims & Hers Health had its price target lowered by Jefferies Financial Group from $31.00 to $24.00. They now have a “hold” rating on the stock.
• 11/10/2026 – Hims & Hers Health had its price target lowered by Morgan Stanley from $28.00 to $25.00. They now have an “equal weight” rating on the stock.
• 11/10/2026 – Hims & Hers Health had its price target lowered by Needham & Company LLC from $42.00 to $32.00. They now have a “buy” rating on the stock.
• 11/4/2026 – Hims & Hers Health had its “sell (d)” rating reaffirmed by Weiss Ratings.

Hims & Hers Health Stock Down 17.0%

Hims & Hers Health stock opened at $19.03 on Wednesday. The firm has a market cap of $4.44 billion, a price-to-earnings ratio of -22.93 and a beta of 2.53. The company has a debt-to-equity ratio of 4.21, a current ratio of 0.93 and a quick ratio of 0.87. Hims & Hers Health, Inc. has a fifty-two week low of $13.74 and a fifty-two week high of $41.28. The firm has a fifty day moving average price of $28.10 and a two-hundred day moving average price of $26.85.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings results on Monday, August 10th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.32). The firm had revenue of $753.21 million for the quarter, compared to the consensus estimate of $698.90 million. Hims & Hers Health had a negative net margin of 6.65% and a negative return on equity of 9.17%. The firm’s revenue was up 38.2% on a year-over-year basis. During the same quarter last year, the company earned $0.17 earnings per share. As a group, analysts forecast that Hims & Hers Health, Inc. will post -0.16 earnings per share for the current year.

Insiders Place Their Bets

In related news, insider Deborah M. Autor sold 16,773 shares of the stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $27.85, for a total transaction of $467,128.05. Following the completion of the sale, the insider owned 48,961 shares in the company, valued at $1,363,563.85. This represents a 25.52% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Soleil Boughton sold 25,111 shares of the firm’s stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $27.55, for a total value of $691,808.05. Following the completion of the sale, the insider directly owned 313,964 shares in the company, valued at $8,649,708.20. This trade represents a 7.41% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 133,905 shares of company stock valued at $3,826,977. Company insiders own 11.76% of the company’s stock.

Hims & Hers Health, Inc. operates a consumer-focused telehealth platform that connects patients with licensed healthcare providers and offers access to treatments and wellness products. Its services include online consultations, prescription care and over-the-counter products. The company serves a range of health needs, including hair loss, sexual health, skin care, mental health and weight management. Its platform also offers primary care and other services, with offerings varying by location and individual eligibility.